Literature DB >> 1463779

1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.

G Vaidyanathan1, M R Zalutsky.   

Abstract

No-carrier-added 1-(m-[211At]astatobenzyl)guanidine ([211At]MABG) was synthesized by astato demetalation using two different routes. The overall yield for the two-step approach from 3-(tri-n-butylstannyl)benzylamine was 13%. N-Chlorosuccinimide-mediated astato desilylation of 1-[3-(trimethylsilyl)benzyl]guanidine in acetic acid gave poor yields. In trifluoroacetic acid, the reaction worked well. The radiochemical yield was independent of reaction time and the amount of precursor used; however, the temperature of the reaction had a marked effect. Yields of 85% were obtained in 5 min at 70 degrees C using 0.5 mumol of the precursor. The percentage specific binding in vitro of [211At]MABG was nearly constant over a 2-log activity range and was comparable to that of no-carrier-added [131]MIBG. The accumulation of [211At]MABG in the heart and adrenals of normal mice was similar to that observed for no-carrier-added [131]MIBG.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463779     DOI: 10.1021/bc00018a006

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  18 in total

Review 1.  Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2011-10

Review 2.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

3.  A kit method for the high level synthesis of [211At]MABG.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

4.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

5.  Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates.

Authors:  K Kramer; N K Cheung; J Humm; G DiResta; E Arbit; S Larson; R Finn; M Rosenblum; H Nguyen; G Gonzalez; C Liu; Y F Yang; M E Mendelsohn; A P Gillio
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

Review 6.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

Review 7.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

8.  Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.

Authors:  D K Strickland; G Vaidyanathan; H S Friedman; M R Zalutsky
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 9.  Current Consensus on I-131 MIBG Therapy.

Authors:  Daiki Kayano; Seigo Kinuya
Journal:  Nucl Med Mol Imaging       Date:  2018-05-03

10.  Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.

Authors:  Ganesan Vaidyanathan; Ronnie C Mease; Il Minn; Jaeyeon Choi; Ying Chen; Hassan Shallal; Choong Mo Kang; Darryl McDougald; Vivek Kumar; Martin G Pomper; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-01-23       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.